ライフサイエンスコーパス: pregnancy termination

1 t 10.8+/-3.7 weeks, and 7 underwent elective pregnancy termination.

2 trophoblastic neoplasia at the time of their pregnancy termination.

3 sfer back to patients, with no potential for pregnancy termination.

4 ths occurring up to 1 year after delivery or pregnancy termination.

5 egnancies; necropsy was done in two cases of pregnancy termination.

6 on rates of prenatal diagnosis and elective pregnancy termination.

7 n, were enrolled and followed until birth or pregnancy termination.

8 edication management, and medical aspects of pregnancy termination.

9 fers the option to donate fetal tissue after pregnancy termination.

10 a rat model, following a clear initiation of pregnancy termination.

11 deaths during pregnancy or within 1 year of pregnancy termination.

12 ated with significant increase of fetal loss/pregnancy termination.

13 rostol alone is a highly effective method of pregnancy termination.

14 e fetal tissue for biomedical research after pregnancy termination.

15 to maternal and fetal health, and potential pregnancy termination.

16 74 (22%) miscarriages, and 74 (22%) elective pregnancy terminations.

17 lities, detected by fetal ultrasound, led to pregnancy terminations.

18 rum collected from elective second trimester pregnancy terminations.

19 from material obtained after first-trimester pregnancy terminations.

20 ple unwanted pregnancies (2.36 [1.90-2.94]), pregnancy termination (1.48 [1.34-1.63]), and female ste

21 abortions, 18 intrauterine fetal demise, 672 pregnancy terminations and 87 were lost to follow-up.

22 an 24 months, multiple unwanted pregnancies, pregnancy termination, and sterilisation all remained si

23 using a high number of stillbirths, elective pregnancy terminations, and child mortality; India contr

24 sociated with greater adjusted odds of prior pregnancy termination (AOR 1.64, 95% CI 1.52-1.77, p < 0

25 e differential use of prenatal diagnosis and pregnancy termination between low-parity and high-parity

26 ng pregnancy or within 1 year of delivery or pregnancy termination, by source of data and cause of de

27 live births and stillbirths (including late-pregnancy terminations) delivered at >/=20 weeks' gestat

28 Any previous pregnancy termination/fetal loss was also associated wit

29 The 2016 ISTH guidance against elective pregnancy termination for fear of DOAC embryotoxicity an

30 disease as well as recommendations regarding pregnancy termination for women at excessive cardiovascu

31 Significantly more pregnancy terminations had been done in women with throm

32 ortion cutoffs, prohibiting consideration of pregnancy termination if concerns about teratogenic effe

33 eversal of an initiated mifepristone-induced pregnancy termination in a rat model at first-trimester

34 following initiation of mifepristone-induced pregnancy termination (indicated by weight loss and uter

35 age at first birth, and other risk factors, pregnancy termination (induced or spontaneous) was assoc

36 imilar to that of the M+P- group (confirming pregnancy termination initiation), number of gestational

37 : Pregnant control (M-P-), mifepristone-only/pregnancy termination (M+P-) and mifepristone + progeste

38 r, data on interbirth intervals suggest that pregnancy termination offers fitness benefits for female

39 etal and embryonic tissues donated following pregnancy terminations or fertility treatment.

40 icant comorbidities resulted in an increased pregnancy termination rate in the first trimester.

41 eening test sensitivity and specificity, and pregnancy termination rates on the results.

42 women during pregnancy or within 42 days of pregnancy termination to livebirths.

43 e potential reversal of mifepristone-induced pregnancy termination using progesterone in a rat model,

44 del, poor obstetrical outcome (fetal loss or pregnancy termination) was associated with history of se

45 Few pregnancy terminations were reported as a result of such